News

Under the terms of the agreement, KM Biologics will carry out the development, manufacturing, and commercialisation of Osivax’s vaccine. KM Biologics will make an upfront payment to Osivax

RA Capital Management spearheaded the financing round with contributions from current investors namely Insight Partners, NVentures and Gaingels. New participants in this funding round included Catalio Capital Management,

This recommendation will aid in the potential authorisation of the vaccine for use in individuals aged six months and older to prevent Covid-19 in the upcoming 2024-2025 autumn/winter

The first facility is breaking ground at the Novartis site in Indianapolis, dedicated to the production of radioisotopes essential for RLT manufacturing. This expansion is set to bolster

With the MHRA approval, the updated vaccine will be included in the National Health Service (NHS) autumn vaccination programme. The company noted that the vaccine will be given

SKG1108 is a one-time intravitreally delivered therapy, which uses a recombinant adeno-associated virus (rAAV) vector to target the condition. It employs the AAV.0106 capsid to deliver a single-stranded

The Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) [NVX-CoV2705] is now authorised for active immunisation against Covid-19. Following the EUA, the vaccine is also recommended by the US Centers

The application is supported by findings from the Phase III Vivacity-MG3 clinical trial. Assessing the improvement in the MG-ADL score from baseline over 24 weeks was the primary

lncRNAs are a class of therapeutic targets that play a critical role in disease by recruiting RNA-binding proteins (RBPs). The companies will focus on advancing two oncology programmes